The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

BTOG 2020 | The impact of brain metastasis

Name: The impact of brain metastasis
Uploaded: 2020-01-30T00:00:00Z
Duration: 2 min 5 s
Description: Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses the issue of brain metastasis and the lack of drugs that prevent this type of progression, highlighting osimertinib as a potential drug to reduce these negative outcomes. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Samreen Ahmed • 30 Jan 2020

BTOG 2020

Lung Cancer Gefitinib Osimertinib

Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses the issue of brain metastasis and the lack of drugs that prevent this type of progression, highlighting osimertinib as a potential drug to reduce these negative outcomes. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.